Proteinuria: Is the ONTARGET renal substudy actually off target?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it.

1. Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials.Hypertension research : official journal of the Japanese Society of Hypertension · 2019
   Pooled it
2. Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis.Journal of the American Society of Nephrology : JASN · 2015
   Pooled it
3. Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.Journal of the American Society of Nephrology : JASN · 2015
   Pooled it
4. Addition of aliskiren to Angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease.International journal of molecular sciences · 2013
   Trial
5. The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2013
   Trial
6. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.Clinical journal of the American Society of Nephrology : CJASN · 2010
   Trial
7. Achieving remission of proteinuria in childhood CKD.Pediatric nephrology (Berlin, Germany) · 2017
   Observational
8. Recent advances in managing and understanding diabetic nephropathy.F1000Research · 2016
   Review
9. The effect of RAAS blockade on the progression of diabetic nephropathy.Nature reviews. Nephrology · 2014
   Review
10. Improving the efficacy of RAAS blockade in patients with chronic kidney disease.Nature reviews. Nephrology · 2013
    Review
11. Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes.Current diabetes reviews · 2011
    Review
12. The RAAS in the pathogenesis and treatment of diabetic nephropathy.Nature reviews. Nephrology · 2010
    Review
13. The role of renin angiotensin system inhibition in kidney repair.Fibrogenesis & tissue repair · 2010
    Article
14. Renovascular and renoprotective properties of telmisartan: clinical utility.International journal of nephrology and renovascular disease · 2010
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as